You're asking about **1-(5-nitro-2-thiophenyl)piperidine**, a compound with a complex name and a unique structure.
Here's a breakdown:
* **Structure:** This compound consists of two key parts:
* **Piperidine:** A six-membered ring with a nitrogen atom. It's a cyclic amine commonly found in pharmaceuticals.
* **5-nitro-2-thiophenyl:** This is a substituted thiophene ring, meaning it's a five-membered ring containing a sulfur atom. The 5-nitro part indicates a nitro group (NO2) attached at the fifth position, and 2-thiophenyl means the piperidine ring is attached at the second position of the thiophene ring.
* **Importance in Research:**
* **Potential for Drug Development:** Compounds like 1-(5-nitro-2-thiophenyl)piperidine are often studied as **potential drug candidates**. The combination of a piperidine ring and a modified thiophene ring can lead to unique pharmacological properties. Researchers might explore its potential for:
* **Antibacterial activity:** Some thiophene derivatives are known to have antibacterial properties.
* **Anti-inflammatory activity:** The piperidine ring is common in drugs that target inflammation.
* **Neuroprotective effects:** The compound's structure might influence its interaction with the central nervous system.
* **Studying Chemical Reactivity:** This compound could be valuable for studying the **reactivity of thiophene rings** when attached to piperidine. Researchers might investigate:
* **How the nitro group affects the thiophene's chemical behavior.**
* **The compound's potential for reactions and modifications.**
* **Understanding Structure-Activity Relationships:** This compound's structure allows researchers to explore the relationship between **molecular structure and biological activity**. This knowledge can be used to design more effective and targeted drugs.
**Important Note:** The compound you mentioned is not a well-established drug or a widely studied chemical. The information above is based on the general potential of compounds with similar structures.
If you have specific research interests, you should consult scientific databases, research papers, and experts in the field to find more detailed information on 1-(5-nitro-2-thiophenyl)piperidine or related compounds.
ID Source | ID |
---|---|
PubMed CID | 4326087 |
CHEMBL ID | 1520551 |
CHEBI ID | 121793 |
Synonym |
---|
HMS2602E11 |
1-(5-nitrothien-2-yl)piperidine |
MLS000682710 , |
smr000312067 |
CHEBI:121793 |
1-(5-nitrothiophen-2-yl)piperidine |
AKOS002118342 |
cid_4326087 |
1-(5-nitro-2-thiophenyl)piperidine |
bdbm88908 |
1-(5-nitro-2-thienyl)piperidine |
CHEMBL1520551 |
Q27210364 |
Class | Description |
---|---|
thiophenes | Compounds containing at least one thiophene ring. |
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 35.3973 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.1187 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.8489 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 29.9349 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 56.2341 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 70.7946 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 63.0957 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
PSMD14 protein | Homo sapiens (human) | IC50 (µMol) | 36.1000 | 1.3000 | 21.8715 | 50.9000 | AID602368 |
TPA: prothrombin | Bos taurus (cattle) | IC50 (µMol) | 68.0000 | 4.8100 | 36.7432 | 77.4000 | AID602369 |
72 kDa type IV collagenase isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 5.7900 | 38.9633 | 78.4000 | AID602361 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |